#DRMA

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules $4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrantsSAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader

2 months ago

#DRMA #DRMAW Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Dec 4th - #YB #NA #MAMO #LASE #DRMA #CNTX #SYBX #SVCO #PLRX #NDRA #KITT #EKSO #CBIO #BBNX #ZKH #NOAH #GCO #ECVT #BBW - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Dermata Therapeutics (Nasdaq: DRMA) announced a strategic pivot to develop and commercialize over-the-counter dermatology products and reported Q3 2025 results. The company plans to launch a once-weekly acne kit using its Spongilla technology in mid-2026 and is developing branding, packaging, and manufacturing for direct-to-consumer and professional sales.Recent clinical progress includes positive topline Phase 3 STAR-1 results that met all three primary endpoints and showed separation from placebo by week 4. As of September 30, 2025, Dermata had $4.7 million in cash and expects funding into Q2 2026.

4 months ago

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

Once-Weekly Acne Treatment Breakthrough: Dermata's Novel Technology Gets Australian Patent Green Light Dermata's Spongilla technology for once-weekly OTC acne treatment receives Australian patent acceptance. Set to launch mid-2026, targeting 3.3M Australian acne patients.

5 months ago

#DRMA #DRMAW Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

www.stocktitan.net/news/DRMA/dermata-announ...

0 0 0 0

Once-Weekly Acne Treatment Breakthrough: Dermata's XYNGARI Phase 3 Results Coming to Major European Congress Dermata Therapeutics to present Phase 3 STAR-1 trial results for XYNGARI (DMT310), a novel once-weekly topical treatment for moderate-to-severe acne, at EADV Congress 2025 in Paris.

5 months ago

#DRMA #DRMAW Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

50 Million Patient Market: Dermata's Strategic Shift to OTC Could Revolutionize Acne Treatment Access Biotech firm Dermata transitions from prescription drugs to OTC skincare, leveraging Spongilla technology for new acne treatment launching mid-2026. Strategic pivot aims to reach broader consumer base.

6 months ago

#DRMA #DRMAW Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

New Acne Treatment XYNGARI Shows Success in Just 4 Weeks - Phase 3 Trial Results Revealed Dermata's XYNGARI achieves statistically significant results for moderate-to-severe acne in Phase 3 trial, with efficacy shown at 4 weeks. Funding secured through Q2 2026. Learn more.

7 months ago

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

Breakthrough: First-Ever Topical Botulinum Toxin for Hyperhidrosis Receives Australian Patent Dermata secures Australian patent for innovative DMT410 topical botulinum toxin delivery system. Partners with Revance for clinical trials. Learn about this breakthrough.

8 months ago

#DRMA #DRMAW Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

www.stocktitan.net/news/DRMA/dermata-receiv...

0 0 0 0

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Dermata Therapeutics (NASDAQ: DRMA) reported significant progress in Q1 2025, highlighted by positive topline results from its XYNGARI™ Phase 3 STAR-1 clinical trial for moderate-to-severe acne treatment. The trial achieved all three co-primary endpoints with statistical significance versus placebo, showing efficacy after just 4 weeks. The company also entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 with DAXXIFY® for axillary hyperhidrosis treatment.Financially, Dermata raised $8.8 million in gross proceeds during Q1 2025, ending the quarter with $9.7 million in cash. R&D expenses decreased to $1.3 million from $1.6 million year-over-year, while G&A expenses reduced to $1.1 million from $1.6 million. The company expects current cash resources to fund operations into Q1 2026.The company plans to initiate its second Phase 3 STAR-2 trial by end of 2025 and is in partnership discussions for XYNGARI™.

10 months ago

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks Dermata Therapeutics (NASDAQ:DRMA) has announced additional positive results from its Phase 3 STAR-1 trial for XYNGARI™, a potential first-ever once-weekly topical treatment for moderate-to-severe acne. The trial demonstrated statistically significant efficacy after just four treatments at week 4.Key results at week 4 showed:11.9% of XYNGARI™ patients achieved IGA treatment success vs 6.2% for placebo (pMean inflammatory lesion count reduction of -11.4 for XYNGARI™ vs -8.6 for placebo (pMean non-inflammatory lesion count reduction of -12.4 for XYNGARI™ vs -8.8 for placebo (pThe STAR-1 study enrolled 520 patients aged 9+ years across the US and Latin America in a 2:1 randomized, double-blind, placebo-controlled trial. This is the first of two pivotal Phase 3 studies, with successful results potentially supporting a future FDA new drug application.

10 months ago

#DRMA #DRMAW Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

www.stocktitan.net/news/DRMA/dermata-s-xyng...

0 0 0 0

NewYork

@newyork.activitypub.awakari.com.ap.brid.gy

11 months ago

Original post on benzinga.com

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And G...

www.benzinga.com/general/market-summary/2...

#AIR […]

[Original post on benzinga.com]

0 0 0 0

Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement Biotech firm secures immediate $6.2M through warrant restructuring, strengthening cash position for clinical trials and R&D pipeline. Full investment implications inside.

11 months ago

#DRMA #DRMAW Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

11 months ago

BREAKING NEWS: ( NASDAQ: #DRMA ) Dermata's XYNGARI Nails Phase 3: A Once-Weekly Acne Breakthrough

0 0 0 0

First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial Novel once-weekly XYNGARI shows significant efficacy in 520-patient Phase 3 trial for moderate-severe acne. Strong safety profile positions treatment for FDA submission.

11 months ago

#DRMA #DRMAW BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

www.stocktitan.net/news/DRMA/breaking-derma...

0 0 0 0

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results Dermata Therapeutics (NASDAQ:DRMA) provided its year-end 2024 financial results and corporate updates. The company expects to announce topline results from its XYNGARI™ Phase 3 STAR-1 clinical trial for moderate-to-severe acne by end of March 2025.Key financial highlights include:Cash position of $3.2M as of December 31, 2024R&D expenses increased to $8.2M in 2024 from $4.1M in 2023G&A expenses rose to $4.3M from $4.0M year-over-yearRaised $7.8M in gross proceeds during 2024Notable developments include a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 for axillary hyperhidrosis treatment, and a $2.55M private placement in January 2025. The company expects current cash resources to fund operations into Q3 2025.

11 months ago

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

Can Dermata's Once-Weekly Acne Treatment Disrupt a 30M-Patient Market? Final patient completes STAR-1 trial for novel once-weekly acne therapy targeting 30M+ patients annually. Topline results expected by March 2025.

1 year ago

#DRMA #DRMAW Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

www.stocktitan.net/news/DRMA/dermata-announ...

1 0 0 0

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis Dermata Therapeutics (NASDAQ: DRMA) announced the Australian Patent Office has accepted its patent application for the DMT410 program for treating hyperhidrosis. This would be Dermata's second patent for DMT410, which uses Spongilla technology to topically deliver botulinum toxin for excessive sweating treatment.The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for axillary hyperhidrosis. The upcoming Phase 2a study will explore DMT410's combination of a single XYNGARI™ application followed by a topical application of DAXXIFY®.Gerry Proehl, Dermata's Chairman, President, and CEO, stated the acceptance further validates DMT410's innovative approach. Beyond hyperhidrosis, the company believes DMT410 holds promise for treating various skin conditions, including acne, rosacea, melasma, acne scars, and other aesthetic concerns.The patent, entitled "Compositions for the treatment of skin conditions," will be automatically issued three months after acceptance unless opposed by a third party. Dermata also has an issued patent in Japan covering their DMT410 program for hyperhidrosis treatment.

1 year ago

#DRMA #DRMAW Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

www.stocktitan.net/news/DRMA/dermata-receiv...

0 0 0 0

Dermata Therapeutics Secures $2.55M Private Placement with Strong Insider Participation Dermata raises $2.55M through share & warrant offering at $1.27/share, backed by CEO & board member investments. Funding targets research, clinical trials & working capital.

1 year ago

#DRMA #DRMAW Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

Dermata and Revance Partner on First Needle-Free Botulinum Treatment for Excessive Sweating Phase 2a trial combines Xyngari's innovative delivery system with Daxxify for treating hyperhidrosis, potentially revolutionizing treatment without needles. 48 patients to be evaluated.

1 year ago

#DRMA #DRMAW Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

www.stocktitan.net/news/DRMA/dermata-and-re...

0 0 0 0

Dermata Completes Phase 3 Trial Enrollment for Novel Weekly Acne Treatment | DRMA Stock News Dermata Therapeutics reaches milestone with 520 patients enrolled in pivotal Phase 3 STAR-1 trial for DMT310, a potential first-in-class weekly acne treatment. Results due March 2025.

1 year ago

#DRMA #DRMAW Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

#clinicaltrial #StockMarket #news

www.stocktitan.net/news/DRMA/dermata-comple...

0 0 0 0

1 year ago

#DRMA #DRMAW Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

www.stocktitan.net/news/DRMA/dermata-therap...

0 0 0 0

1 year ago

NEWS: ( NASDAQ: #DRMA ) Dermata Therapeutics Inc. (NASDAQ: DRMA) Leading the Way in Friday Trading Based on Percentage Gain

#StockMarket #News

1 0 0 0

1 year ago

Breaking News: ( NASDAQ: #DRMA ) Dermata Therapeutics Inc. (NASDAQ: DRMA) Near the Top of Equities by Percentage Gain on 8/1

#StockMarket #News

1 0 0 0

1 year ago

Breaking News: ( NASDAQ: #DRMA ) Dermata Therapeutics Inc. (NASDAQ: DRMA) Leading the Way in Wednesday Trading Based on Percentage Gain

#StockMarket #News

0 0 0 0